Skip to main content
main-content

ESMO Congress 2021 coverage

NEWS AND EXPERT VIDEO INTERVIEWS FROM THE MEETING

Expert video interviews

18-09-2021 | ESMO 2021 | Conference coverage | Video

Promising early results for cetrelimab plus erdafitinib reported for advanced UC

Thomas Powles explains why the interim results of the NORSE trial of first-line cetrelimab plus erdafitinib in FGFR-altered advanced urothelial cancer not only justify its continuance, but also point to the need for larger studies of the combination in this setting.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Latest research news | Breast cancer

Latest research news | COVID-19

Latest research news | Genitourinary cancers

Latest research news | Thoracic cancers

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Our trial recommendations from the meeting

Expand to view. Browse selections by swiping horizontally or by using the < > arrows.


Medicine Matters conference coverage is brought to you in partnership with medwireNews



Image Credits